{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:38:33Z","timestamp":1791923913739,"version":"4.3.4"},"reference-count":28,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,2,1]]},"abstract":"<jats:p>Recent studies have defined a link between the renin-angiotensin-aldosterone system and fibrinolysis. The present study tests the hypothesis that endogenous aldosterone regulates plasminogen activator inhibitor-1 (PAI-1) production in humans. Hemodynamic parameters, PAI-1 and tissue-type plasminogen activator (t-PA) antigen, potassium, PRA, angiotensin II, and aldosterone were measured in nine male hypertensive subjects after a 3-wk washout, after 2 wk of hydrochlorothiazide (HCTZ; 25 mg plus 20 mmol KCl\/d), and after 2 wk of spironolactone (100 mg\/d plus KCl placebo). Spironolactone (P = 0.04), but not HCTZ (P = 0.57 vs. baseline; P = 0.1 vs. spironolactone), significantly lowered systolic blood pressure. Angiotensin II increased from baseline during both HCTZ (P = 0.02) and spironolactone (P = 0.02 vs. baseline; P = 0.19 vs. HCTZ) treatments. Although both HCTZ (P = 0.004) and spironolactone (P &amp;lt; 0.001 vs. baseline) increased aldosterone, the effect was greater with spironolactone (P &amp;lt; 0.001 vs. HCTZ). HCTZ increased PAI-1 antigen (P = 0.02), but did not alter t-PA antigen. In contrast, there was no effect of spironolactone on PAI-1 antigen (P = 0.28), whereas t-PA antigen was increased (P = 0.01). There was a significant correlation between PAI-1 antigen and serum aldosterone during both baseline and HCTZ study days (r2 = 0.57; P = 0.0003); however, treatment with spironolactone abolished this correlation (r2 = 0.13; P = 0.33). This study provides evidence that endogenous aldosterone influences PAI-1 production in humans.<\/jats:p>","DOI":"10.1210\/jcem.87.2.7980","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T17:08:04Z","timestamp":1389200884000},"page":"448-452","source":"Crossref","is-referenced-by-count":66,"title":["Spironolactone Abolishes the Relationship between Aldosterone and Plasminogen Activator Inhibitor-1 in Humans"],"prefix":"10.1210","volume":"87","author":[{"given":"Pairunyar","family":"Sawathiparnich","sequence":"first","affiliation":[{"name":"Divisions of Clinical Pharmacology (P.S., S.K., N.J.B.), Tennessee 37232"},{"name":"Pediatric Endocrinology (P.S.), Tennessee 37232"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[{"name":"Divisions of Clinical Pharmacology (P.S., S.K., N.J.B.), Tennessee 37232"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Vaughan","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine (D.E.V.), Vanderbilt University Medical Center, Nashville, Tennessee 37232"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Brown","sequence":"additional","affiliation":[{"name":"Divisions of Clinical Pharmacology (P.S., S.K., N.J.B.), Tennessee 37232"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071616555620900_R1","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM199104183241605","article-title":"Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension.","volume":"324","author":"Alderman","year":"1991","journal-title":"N Engl J Med"},{"key":"2020071616555620900_R2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"2020071616555620900_R3","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0140-6736(92)92889-N","article-title":"Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.","volume":"340","author":"Yusuf","year":"1992","journal-title":"Lancet"},{"key":"2020071616555620900_R4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"2020071616555620900_R5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1172\/JCI117809","article-title":"Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells.","volume":"95","author":"Vaughan","year":"1995","journal-title":"J Clin Invest"},{"key":"2020071616555620900_R6","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1172\/JCI118312","article-title":"Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.","volume":"96","author":"Kerins","year":"1995","journal-title":"J Clin Invest"},{"key":"2020071616555620900_R7","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/01.HYP.32.6.965","article-title":"Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1 in humans.","volume":"32","author":"Brown","year":"1998","journal-title":"Hypertension"},{"key":"2020071616555620900_R8","first-page":"336","article-title":"Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production.","volume":"85","author":"Brown","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616555620900_R9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","article-title":"Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.","volume":"58","author":"Brown","year":"2000","journal-title":"Kidney Int"},{"key":"2020071616555620900_R10","first-page":"847","article-title":"Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects.","volume":"93","author":"Workman","year":"1979","journal-title":"J Lab Clin Med"},{"key":"2020071616555620900_R11","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/0196-9781(91)90070-6","article-title":"Reassessment of plasma angiotensin measurement: effects of protease inhibitors and sample handling procedures.","volume":"12","author":"Kohara","year":"1991","journal-title":"Peptides"},{"key":"2020071616555620900_R12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0196-9781(94)90051-5","article-title":"Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats.","volume":"15","author":"Senananyake","year":"1994","journal-title":"Peptides"},{"key":"2020071616555620900_R13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/01.HYP.25.4.796","article-title":"Angiotensin-(1\u20137) and nitric oxide interaction in renovascular hypertension.","volume":"25","author":"Nakamoto","year":"1995","journal-title":"Hypertension"},{"key":"2020071616555620900_R14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00000441-200001000-00004","article-title":"Pharmacology of diuretics.","volume":"319","author":"Brater","year":"2000","journal-title":"Am J Med Sci"},{"key":"2020071616555620900_R15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0895-7061(99)00286-1","article-title":"Fibrinolytic function in diuretic-induced volume depletion.","volume":"13","author":"Lottermoser","year":"2000","journal-title":"Am J Hypertension"},{"key":"2020071616555620900_R16","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.99.20.2694","article-title":"Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis.","volume":"99","author":"Silvestre","year":"1999","journal-title":"Circulation"},{"key":"2020071616555620900_R17","first-page":"4097","article-title":"Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines.","volume":"84","author":"Halleux","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616555620900_R18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1210\/endo.130.1.1309341","article-title":"Spironolactone, an aldosterone antagonist, acts as an antiglucocorticoid on the mouse mammary tumor virus promoter.","volume":"130","author":"Coutte","year":"1992","journal-title":"Endocrinology"},{"key":"2020071616555620900_R19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","article-title":"Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism.","volume":"25","author":"Brilla","year":"1993","journal-title":"J Mol Cell Cardiol"},{"key":"2020071616555620900_R20","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1161\/01.ATV.17.6.1152","article-title":"Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats.","volume":"17","author":"Benetos","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020071616555620900_R21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"2020071616555620900_R22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats.","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"key":"2020071616555620900_R23","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure.","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"key":"2020071616555620900_R24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1172\/JCI118396","article-title":"Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.","volume":"97","author":"Eitzman","year":"1996","journal-title":"J Clin Invest"},{"key":"2020071616555620900_R25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2020071616555620900_R26","first-page":"S81","article-title":"Hydrochlorothiazide impairs fibrinolytic balance in hypertensives","volume":"18","author":"Brown","year":"2000","journal-title":"J Hypertension"},{"key":"2020071616555620900_R27","first-page":"481","article-title":"Activation of the renin-angiotensin system through dietary sodium restriction increases plasminogen activator inhibitor type 1 levels in essential hypertension.","volume":"30","author":"Litchfield","year":"1997","journal-title":"Hypertension"},{"key":"2020071616555620900_R28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0167-5273(96)02711-8","article-title":"Magnesium therapy, fibrinolytic parameters and von Willebrand factor in acute myocardial infarction.","volume":"56","author":"Thogersen","year":"1996","journal-title":"Int J Cardiol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/87\/2\/448\/9155355\/jcem0448.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/87\/2\/448\/9155355\/jcem0448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:26:18Z","timestamp":1594956378000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/87\/2\/448\/2846493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2,1]]},"references-count":28,"aliases":["10.1210\/jc.87.2.448"],"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jcem.87.2.7980","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2,1]]}}}